ADVANCE: DTG + FTC/(TAF or TDF) Noninferior to EFV/FTC/TDF in ART-Naive Patients in South Africa

July 21-24, 2019; Mexico City, Mexico
Phase III trial supports use of DTG-based regimens, with low rates of emergent resistance and no INSTI resistance.
Format: Microsoft PowerPoint (.ppt)
File Size: 250 KB
Released: July 29, 2019

Acknowledgements

Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Dr Karen Ha and Clinical Care Options (CCO): Data suggests there is a role for NNRTIs in current practice, including for patients who have experienced weight gain with INSTI-based ART.

Karen Ha, MD Released: December 6, 2021

Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 1, 2021

Commentary from Dr Juan Luis Mosqueda Gomez on the latest findings from the IMEA 055 FAST study presented at EACS 2021 and how test-and-treat strategies could improve patient care and virologic suppression in Mexico, from Clinical Care Options (CCO)

Juan Luis Mosqueda Gomez, MD, MSc Released: December 1, 2021

Expert commentary on what long-acting ART means for people with HIV, from Dr Jean-Michel Molina and Clinical Care Options (CCO)

Jean-Michel Molina, MD, PhD Released: November 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue